Share this
BioMarin – $720 Million Follow-On Offering
Cooley Advised Jazz Pharmaceuticals on Rule 144A Offering of $575 Million of Exchangeable Senior Notes
BioMarin Pharmaceutical: $720 Million Public Offering of Common Stock
Jazz Pharmaceuticals Acquires Celator for $1.5 Billion
Seattle Genetics: $552 Million Follow-On
Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility
Jazz Pharmaceuticals plc Rule 144A Offering of $575 Million of Exchangeable Senior Notes
Jazz Pharmaceuticals – $575 Million Exchangeable Senior Note Offering
Jazz Pharmaceuticals $125 Million Acquisition of ADX-N05
AcelRx Pharmaceuticals in Public Offering
Jazz Pharmaceuticals in $314.4 million Offering